Clinical trial

Treatment of Postinfectious Irritable Bowel Syndrome and Noninfective Irritable Bowel Syndrome With Gelsectan

Name
348/28-7-2021
Description
Irritable Bowel Syndrome (IBS) is one of the most common conditions diagnosed in gastroenterology practice. Acute infectious gastroenteritis represents the strongest known risk factor for IBS development; a condition known as post-infection IBS (PI-IBS). PI-IBS patients are more likely than sporadic IBS patients to exhibit a diarrhea-predominant phenotype. The investigators plan to prospectively recruit two groups of patients: patients with diarrhea-predominant post-infectious IBSand patients with diarrhea predominant classical IBS (non PI-IBS) who will be used as controls. Patients included in the study will receive for 28 days a capsule containing Tamarind seed polysaccharide containing xyloglucan, combined with a pea protein reticulated with grape seed extractand a prebiotic, the xilooligosaccharide (Gelsectan, Devintec Sagl) twice daily.
Trial arms
Trial start
2021-09-01
Estimated PCD
2024-02-26
Trial end
2024-02-26
Status
Completed
Phase
Early phase I
Treatment
(Gelsectan, Devintec Sagl)
Patients included in the study will receive for 28 days a capsule containing Xyloglucan, Pea Protein and Grape Seed Extract and a prebiotic Xylo-oligosaccharide (Gelsectan, Devintec sagl) twice daily.
Arms:
Postinfectious ibs and diarrhea predominant classical IBS
Size
275
Primary endpoint
Disappearance of diarrhea
After the end of the 28-day administration of xyloglycan
Eligibility criteria
Inclusion Criteria: Patients with diarrhea-predominant post-infectious IBSand patients with diarrhea predominant classical IBS (non PI-IBS) who will be used as controls Diagnosis of IBS will be made according to the ROME iV criteria as following: Recurrent abdominal pain, on average, at least 1 day/week in the last 3 months, associated with two or more of the following criteria: * Related to defecation * Associated with a change in frequency of stool * Associated with a change in form (appearance) of stool. The above-mentioned criteria have to be fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis. Diagnosis of post infectious IBS will be made according to the Rome Foundation Working Team criteria as following: Recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, with symptom onset at least 6 months before diagnosis, associated with two of the following: 1. defecation 2. a change in frequency of stool 3. a change in form (appearance) of stool Symptom development immediately after resolution of acute infectious gastroenteritis Infectious gastroenteritis should be defined by positive stool culture in a symptomatic individual or presence of two of the following acute symptoms (when stool culture not available): 1. fever 2. vomiting 3. diarrhea Exclusion Criteria: * Patients should not meet criteria for IBS before onset of acute illness. * We will exclude patients who are pregnant, who have an oncology history (since these patients might exhibit diarrhea due to their underlying illness) and patients with alcohol dependence (due to the non-compliance shown by these patients) and patients with known hypersensitivity or allergy to any of the ingredients included in Gelsectan.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 275, 'type': 'ACTUAL'}}
Updated at
2024-02-28

1 organization

1 product

1 indication

Product
Gelsectan